Cerebrovascular effects of angiotensin converting enzyme inhibition involve large artery dilatation in rats.
OBJECTIVE
The aim of the study was to selectively examine the effects of converting enzyme inhibition on the large brain arteries by using concomitant inhibition of carbonic anhydrase to cause severe dilatation of mainly parenchymal resistance vessels.


METHODS
Cerebral blood flow was measured using the xenon-133 injection technique in three groups of Wistar rats either during carbonic anhydrase inhibition with acetazolamide (treatment A, n = 8), during carbonic anhydrase inhibition followed by converting enzyme inhibition with captopril 40 minutes later (treatment B, n = 10), or during carbonic anhydrase inhibition preceded by converting enzyme inhibition 20 minutes earlier (treatment C, n = 7).


RESULTS
After treatment A, cerebral blood flow rose rapidly and stabilized within 20 minutes at an average of 220 ml/100 g.min; flow remained stable until at least 60 minutes. After treatment B, cerebral blood flow increased by a further 17.4%, from an average of 219 ml/100 g.min to an average of 257 ml/100 g.min (p less than 0.01). After treatment C, cerebral blood flow stabilized at an average of 238 ml/100 g.min, with flow from 20 to 60 minutes always being higher (from 5% to 17%) than during carbonic anhydrase inhibition alone (p less than 0.02). Thus the additional inhibition of converting enzyme resulted in higher cerebral blood flow than during inhibition of carbonic anhydrase alone.


CONCLUSIONS
These results suggest that converting enzyme inhibition reduced resistance of large brain arteries and support the hypothesis that there is some angiotensin II-induced tone in large cerebral arteries.
Postiglione
A
A
Neurobiology Research Group, Rigshospitalet, Copenhagen, Denmark.
Bobkiewicz
T
T
Vinholdt-Pedersen
E
E
Lassen
N A
NA
Paulson
O B
OB
Barry
D I
DI
D000086:Acetazolamide / Q000494:pharmacology; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D002216:Captopril / Q000494:pharmacology; D002245:Carbon Dioxide / Q000097:blood; D002257:Carbonic Anhydrase Inhibitors / Q000494:pharmacology; D002536:Cerebral Arteries / Q000187:drug effects* / Q000201:enzymology; D002560:Cerebrovascular Circulation / Q000187:drug effects*; D008297:Male; D010313:Partial Pressure; D051381:Rats; D011919:Rats, Inbred Strains; D014664:Vasodilation
D000806:Angiotensin-Converting Enzyme Inhibitors; D002257:Carbonic Anhydrase Inhibitors; D002245:Carbon Dioxide; D002216:Captopril; D000086:Acetazolamide